Imperial College London
Alternate

ProfessorJaneMitchell

Faculty of Medicine, National Heart & Lung Institute

Professor of Pharmacology in Critical Care Medicine
 
 
 
//

Contact

 

+44 (0)20 7351 8137j.a.mitchell

 
 
//

Assistant

 

Ms Lisa Quinn +44 (0)20 7594 1345

 
//

Location

 

Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Leadbeater:2011:10.1111/j.1538-7836.2011.04450.x,
author = {Leadbeater, PDM and Kirkby, NS and Thomas, S and Dhanji, A-R and Tucker, AT and Milne, GL and Mitchell, JA and Warner, TD},
doi = {10.1111/j.1538-7836.2011.04450.x},
journal = {Journal of Thrombosis and Haemostasis},
pages = {2050--2056},
title = {Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel},
url = {http://dx.doi.org/10.1111/j.1538-7836.2011.04450.x},
volume = {9},
year = {2011}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Summary. Background: Strong P2Y12 blockade, as can be achieved with novel antiplatelet agents such as prasugrel, has been shown in vitro to inhibit both ADP and thromboxane A2mediated pathways of platelet aggregation, calling into question the need for the concomitant use of aspirin. Objective: The present study investigated the hypothesis that aspirin provides little additional antiaggregatory effect in a group of healthy volunteers taking prasugrel. Study participants/methods: In all, 9 males, aged 18 to 40 years, enrolled into the 21day study. Prasugrel was loaded at 60 mg on day 1 and maintained at 10 mg until day 21. At day 8, aspirin 75 mg was introduced and the dose increased to 300 mg on day 15. On days 0, 7, 14 and 21, platelet function was assessed by aggregometry, response to treatments was determined by VerifyNow™ and urine samples were collected for quantification of prostanoid metabolites. Results: At day 7, aggregation responses to a range of platelet agonists were reduced and there was only a small further inhibition of aggregation to TRAP6, collagen and epinephrine at days 14 and 21, when aspirin was included with prasugrel. Urinary prostanoid metabolites were unaffected by prasugrel, and were reduced by the addition of aspirin, independent of dose. Conclusions: In healthy volunteers, prasugrel produces a strong antiaggregatory effect, which is little enhanced by the addition of aspirin. The addition of aspirin as a dualtherapy with potent P2Y12 receptor inhibitors warrants further investigation.
AU  - Leadbeater,PDM
AU  - Kirkby,NS
AU  - Thomas,S
AU  - Dhanji,A-R
AU  - Tucker,AT
AU  - Milne,GL
AU  - Mitchell,JA
AU  - Warner,TD
DO  - 10.1111/j.1538-7836.2011.04450.x
EP  - 2056
PY  - 2011///
SN  - 1538-7836
SP  - 2050
TI  - Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel
T2  - Journal of Thrombosis and Haemostasis
UR  - http://dx.doi.org/10.1111/j.1538-7836.2011.04450.x
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000295382900021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2011.04450.x
UR  - http://hdl.handle.net/10044/1/87678
VL  - 9
ER  -
Download